Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC

Introduction: In an earlier report of the ASCEND-8 study (open-label, phase I, three-arm study, treatment-naive patients and pre-treated patients with advanced/metastatic NSCLC), it was shown that ceritinib 450 mg with food had comparable exposure and better gastrointestinal tolerability than 750-mg fasted. Conclusion: Ceritinib at a dose of 450 mg with food compared to 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.03.002

Authors: Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, Mark McKeage, Dong-Wang Kim, Ullas Batra, Gloria Borra, Sergey Orlov, Sang-We Kim, Sarayut L. Geater, Pieter E. Postmus, Scott A. Laurie, Keunchil Park, Cheng-Ta Yang, Andrea Ardizzoni, Anna C. Bettini, Gilberto de Castro Jr., Flavia Kiertsman, Zhe Chen, Yvonne Y. Lau, Kalyanee Viraswami-Appanna, Vanessa Q. Passos, Rafal Dziadziuszko

Real-World OutcomesKirk SmithMarch 6, 2019Ceritinib, ALK receptor tyrosine kinase (RTK), NSCLC, Food effect

Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC

Introduction: We retrospectively analyzed the effects of crizotinib on serum creatinine and creatinine-based estimated glomerular filtration rate (eGFR) in patients with anaplastic lymphoma kinase–positive advanced NSCLC across four trials (NCT00585195, NCT00932451, NCT00932893, and NCT01154140). Conclusions: Crizotinib resulted in a decline in creatinine-based estimates of renal function mostly over the first 2 weeks of treatment. However, there was minimal evidence of cumulative effects with prolonged treatment and these changes were largely reversible following treatment discontinuation, consistent with previous reports suggesting this may be predominantly an effect on creatinine secretion as opposed to true nephrotoxicity. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.02.015

Authors: D. Ross Camidge, Elizabeth E. Kim, Tiziana Usari, Anna Polli,Iona Lewis and Keith D. Wilner

Clinical TrialsKirk SmithFebruary 26, 2019Crizotinib, ALK receptor tyrosine kinase (RTK), NSCLC, Renal function, Estimated glomerular filtration rate